Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Evaluating JIA Assessment Instruments (3 of 3)
There are three test characteristics that are used to describe outcome assessment tools. They are validity, which is defined as how well an instrument measures what it claims to measure; reliability, which is the consistency of the instrument in measuring the construct of interest (reproducibility is the test-retest reliability); and responsiveness, which is determined by two properties: (1) reproducibility and (2) the ability to register changes in scores when a patient’s symptom status shows clinically important improvement or deterioration.
Keywords: anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | reliability | responsiveness | rheumatic | TNF-alpha blockers | validity | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.